US stock · Healthcare sector · Medical Devices
Company Logo

Bruker Corporation

BRKRNASDAQ

48.92

USD
+0.01
(+0.02%)
After Hours Market
27.17P/E
19Forward P/E
1.36P/E to S&P500
7.247BMarket CAP
0.37%Div Yield
Upcoming Earnings
31 Oct-4 Nov
Shares Short
8/31/22
2.05M
Short % of Float
2.88%
Short % of Shares Outs.
1.38%
% Held by Insiders
32.55%
% Held by Institutions
71.29%
Beta
1.22
PEG Ratio
1.28
52w. high/low
87.22/48.42
Avg. Daily Volume
0.69M
Return %
Stock
S&P 500
1 year
(39.90)
(17.80)
3 years
9.49
23.21
5 years
65.85
45.98
Scale: |
High
Low
13.49
6.30
17.22
3.07
12.49
3.25
17.65
10.52
21.65
11.48
17.10
9.91
21.33
15.41
24.93
17.26
25.23
15.78
29.85
19.59
36.53
21.20
36.49
26.10
52.23
28.02
55.87
30.78
92.35
53.06
83.69
48.61
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
4.29
5.28
6.80
6.82
7.94
9.99
10.79
11.05
10.78
9.65
9.98
11.17
12.14
13.35
12.96
15.76
16.45
Earnings per share
0.18
0.30
0.40
0.50
0.58
0.56
0.47
0.48
0.34
0.60
0.95
0.50
1.15
1.27
1.03
1.81
1.82
FCF per share
0.30
0.12
0.37
0.82
0.76
0.20
0.36
0.57
0.48
1.16
0.58
0.70
1.22
0.90
1.53
1.24
0.76
Dividends per share
- -
- -
0.14
- -
0.00
- -
- -
- -
- -
- -
0.16
0.16
0.16
0.16
0.16
0.16
0.18
CAPEX per share
0.08
0.16
0.29
0.10
0.19
0.33
0.44
0.30
0.20
0.20
0.23
0.28
0.31
0.47
0.63
0.60
0.54
Book Value per sh.
1.89
2.49
1.92
2.55
3.19
3.76
4.26
5.08
4.56
4.32
4.25
4.59
5.74
5.84
6.27
7.07
6.91
Comm.Shares outs.
102
104
163
164
164
165
166
167
168
168
161
158
156
155
153
153
151
Avg. annual P/E ratio
33.0
30.0
28.7
16.5
23.8
29.9
29.7
37.9
62.7
32.6
25.3
56.0
27.7
33.5
42.4
40.4
27.2
P/E to S&P500
1.8
1.7
1.3
0.2
1.1
1.8
2.0
2.2
3.5
1.6
1.1
2.4
1.1
1.4
1.1
1.3
1.4
Avg. annual div. yield
- -
- -
1.3%
- -
0.0%
- -
- -
- -
- -
- -
0.7%
0.6%
0.5%
0.4%
0.4%
0.2%
0.3%
Revenue (m)
436
548
1,107
1,115
1,305
1,652
1,791
1,839
1,809
1,624
1,611
1,766
1,896
2,073
1,988
2,418
2,476
Operating margin
7.0%
9.1%
9.8%
12.3%
11.9%
9.4%
8.7%
8.1%
5.8%
9.0%
11.0%
12.2%
13.8%
14.5%
12.5%
17.1%
16.4%
Depreciation (m)
13
13
30
30
36
3
59
61
60
53
54
64
65
76
80
89
89
Net profit (m)
18
32
65
81
95
92
78
80
57
102
154
79
180
197
158
277
274
Income tax rate
46.3%
34.5%
30.0%
37.3%
35.5%
35.4%
43.5%
34.3%
41.2%
18.0%
13.0%
59.4%
26.0%
29.4%
28.5%
28.7%
29.5%
Net profit margin
4.2%
5.8%
5.9%
7.3%
7.3%
5.6%
4.3%
4.4%
3.1%
6.3%
9.5%
4.5%
9.5%
9.5%
7.9%
11.5%
11.0%
Working capital (m)
100
143
301
333
220
438
628
783
784
677
751
834
705
1,151
1,133
1,533
1,269
Long-term debt (m)
23
6
183
116
87
219
336
354
354
266
392
416
323
813
842
1,222
1,171
Equity (m)
191
259
312
417
525
622
707
846
766
726
686
725
897
907
961
1,085
984
ROIC
7.8%
10.6%
10.9%
13.6%
13.9%
10.3%
7.3%
6.7%
5.1%
9.6%
12.9%
6.1%
12.5%
9.9%
7.5%
10.3%
10.9%
Return on capital
7.9%
8.7%
8.3%
11.7%
10.0%
8.9%
8.2%
6.9%
6.0%
8.0%
10.5%
10.9%
12.1%
10.7%
7.8%
10.7%
11.7%
Return on equity
9.7%
12.2%
20.8%
19.5%
18.2%
14.9%
11.0%
9.5%
7.4%
14.0%
22.4%
10.8%
20.0%
21.7%
16.4%
25.5%
27.8%
Plowback ratio
100.0%
100.0%
63.9%
100.0%
99.9%
100.0%
100.0%
100.0%
100.0%
100.0%
83.2%
67.7%
86.0%
87.3%
84.4%
91.3%
90.1%
Div.&Repurch./FCF
(5.3)%
(161.4)%
33.1%
(1.1)%
(4.8)%
(9.9)%
(7.5)%
(8.7)%
(9.8)%
40.6%
186.0%
142.4%
8.2%
111.4%
61.5%
89.5%
233.4%
Capital Structure
30 Jun · 2022 | Q2
All numbers in millions
Total liabilities
$ 2,400
Total assets
$ 3,385
Long-term debt
$ 1,171
Cash and equiv.
$ 723
Goodwill
$ - -
Retained earnings
$ 57
Common stock
149
Enterprise Value
$ 7,695
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
685
732
1,168
Receivables
362
335
417
Inventory
577
692
710
Other
172
169
567
Current assets
1,796
1,925
2,472
Acc. Payable
118
135
147
Debt due
21
24
112
Other
506
634
679
Current liabilities
646
792
939
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
21.66%
8.56%
3.76%
Cash flow
(18.98)%
23.55%
27.19%
Earnings
75.60%
48.50%
27.74%
Dividends
(1.63)%
(1.20)%
- -
Book value
12.84%
10.89%
5.43%
Insider Trading
Type
Shares
Date
Busse Falko
Award
4,719
08/11/22
Busse Falko
Award
4,658
08/11/22
Prause Burkhard
Award
2,472
08/11/22
Prause Burkhard
Award
2,440
08/11/22
Herman Gerald N
Award
12,686
08/11/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
424
425
511
628
1,988
2021
555
571
609
684
2,418
2022
595
588
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.07
0.16
0.35
0.45
1.03
2021
0.37
0.38
0.57
0.49
1.81
2022
0.41
0.33
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.04
0.04
0.04
0.04
0.16
2021
0.04
0.04
0.04
0.04
0.16
2022
0.05
0.05
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Dr. Frank Laukien
Full-time employees:
7,765
City:
Billerica
Address:
40 MANNING RD
IPO:
Aug 4, 2000
Website:
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.